title: Moclobemide treatment of clozapine-induced hypersalivation: pilot open study.
abstract: OBJECTIVE
  Clozapine-induced hypersalivation (CIHS) affects a mean of approximately 30% patients and is a troublesome adverse effect that leads to massive compliance problems in patients with schizophrenia. For the management of this distressing adverse effect, different pharmacological agents have been recommended, yet none of them have been proven to be effective. The aim of our study was to investigate moclobemide, a reversible monoamine oxidase inhibitor-A, as an additional possibility for controlling or at least minimizing CIHS.
  
  
  METHODS
  We enrolled 14 patients with schizophrenia who experienced CIHS. Moclobemide (150-300 mg/d) was added to their conventional regular treatment during 14 days. Hypersalivation was assessed at the start of the treatment and at its end point by the 5-point Nocturnal Hypersalivation Rating Scale.
  
  
  RESULTS
  Two thirds of the subjects who experienced CIHS have demonstrated a beneficial effect after the addition of moclobemide, whereas one third of them have been nonresponders. None of the patients had any adverse effects.
  
  
  CONCLUSIONS
  We assume that moclobemide can be another additional and safe medication for the treatment of CIHS; however, more data, based on controlled studies, are needed.
authors.affiliation: Tirat Carmel Mental Health Center, Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.
authors.forename: Anatoly
authors.initials: A
authors.lastname: Kreinin
authors.forename: Chanoch
authors.initials: C
authors.lastname: Miodownik
authors.forename: Igor
authors.initials: I
authors.lastname: Libov
authors.forename: Diana
authors.initials: D
authors.lastname: Shestakova
authors.forename: Vladimir
authors.initials: V
authors.lastname: Lerner
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects; D003024:Clozapine / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020912:Moclobemide / Q000627:therapeutic use*; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D010865:Pilot Projects; D012559:Schizophrenia / Q000188:drug therapy; D012798:Sialorrhea / Q000139:chemically induced / Q000188:drug therapy*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D008996:Monoamine Oxidase Inhibitors; D003024:Clozapine; D020912:Moclobemide